Peer-reviewed Manuscripts

Collectively, members and affiliates of YOLARX have published over 125 publications in high ranking peer reviewed journals and over 150 presentations in scientific conferences.

2017  |  2016 │  2015  2014  │  2013  │  2012  │  2011  │  2010  │  2009 – 2000  │  1999 – 1992

2017

  • Bergamasco A, Nayroles G, Castilloux A-M, Dinet J, Berthon A, Gabriel S, Moride Y. Mitigating the Paucity-of-Data Problem for Target Population Sizing: Exploring a Model-Based Approach for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Med Safe Glo Heal. 2017: 6:1. [published online first: 30 March 2017].
Top

2016

  • Pitts P, Le Louet H, Moride Y, Conti R. 21st Century Pharmacovigilance: Efforts, Roles, and Responsibilities. Lancet Oncol 2016; 17(11):e486–92. doi: 10.1016/S1470-2045(16)30312-6. [published online first: 3 November 2016].
  • Craig C, Tannenbaum C, Ducruet T, Moride Y. Patterns of antipsychotic use among community-dwelling elderly patients with dementia: Impact of regulatory warnings. Med Safe Glo Heal. 2016: 5:129. [published online first: 5 August 2016].
Top

2015

  • Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Drug Saf. 2016 Jan;25(1):2-10. doi: 10.1002/pds.3891. [published online first: 5 November 2015].
  • Xu Y, Zhou X, Suehs BT, Hartzema AG, Kah MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug Saf. 2015;38(8):749-765. doi: 10.1007/s40264-015-0297-5. [publised online first: 9 June 2015].
  • Finkelstein Y, Macdonald EM, Hollands S, Sivilotti ML, Hutson JR, Mamdani MM, Koren G, Juurlink DN (Collaborators:Dormuth CR, Raymond CB, Kozyrskj A, Moride Y, Paterson M.); Canadian Drug Safety and Effectiveness Research Network (CDSERN). Risk of Suicide Following Deliberate Self-poisoning. JAMA Psychiatry. 2015 Jun;72(6):570-5. doi: 10.1001/jamapsychiatry.2014.3188.
Top

2014

  • Beckmann J, Hagemann U, Bahri P, Bate A, Boyd IW, Dal Pan,GJ, Edwards BD, Edwards IR, Hartigan-Go K, Lindquist M, McEwen J, Moride Y, Olsson S, Pal SN, Soulaymani-Bencheikh R, Tuccori M, Vaca CP, Wong IC. Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum. Drug Safety. 2014; Oct; 37(10) :743-759.
  • Billioti de Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. Bmj. 2014; Sept. 9.
  • Gridchyna I, Cloutier AM, Nkeng L, Craig C, Frise S, Moride Y. Methodological gaps in the assessment of risk minimization interventions: a systematic review.  Drug Saf. 2014; Feb.24.
Top

2013

  • Juurlink DN, Dormuth CR, Huang A, Hellings C, Paterson JM, Raymond C, Kozyrskyj A, Moride Y, Macdonald EM, Mamdani MM. Proton pump inhibitors and the risk of cardiac events. PLoS One. 2013 Dec 27;8(12):e84890.
  • Cloutier AM, Greenfield B, Lavoie A, Lynd LD, Tournier M, Brabant MJ, Moride Y. Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants. Psychiatry research, 2013, 209(3), 471-478.
  • Pariente A, Fourrier-Réglat A, Moride Y. Study findings hard to interpret-reply. Arch Intern Med. 2012 Oct 8;172(18):1429-30.
  • Cloutier AM, Greenfield B, Lavoie A, Lynd L, Tournier M, Brabant MJ, Moride Y. Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants.  Psychiatry Research 2013 Oct 30;209(3):471-8.
Top

2012

  • Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ. 2012 Nov 6;184(16):E852-6.
  • Paterson JM, Mamdani MM, Manno M, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012 Oct 2;184(14):1565-70.
  • Béland, SG., Tannenbaum C.. Ducruet, T., Preville M., Moride Y. Effect of external variables on the performance of the Geriatric Comorbidity Score derived from prescription claims in the community-dwelling elderly population. Drugs and Aging, 2012 Nov;29(11):891-7.
  • Préville M, Bossé C, Vasiliadis HM, Voyer P, Laurier C, Berbiche D, Pérodeau G, Grenier S, Béland SG, Dionne PA, Gentil L, Moride Y.Correlates of potentially inappropriate prescriptions of benzodiazepines among older adults: results from the ESA study. Can J Aging. 2012 Sep;31(3):313-22.
  • Paterson JM, Mamdani MM, Manno M, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012 Oct 2;184(14):1565-70.
  • Nkeng L, Cloutier AM, Craig C, Lelorier J, Moride Y. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review. Drug Saf. 2012 Jul 1;35(7):535-46.
  • Pariente A, Fourrier-Réglat A., Béland SG, Ducruet T, Dartigues JF, Moore N, Moride Y Antipsychotics and myocardial infarction in elderly patients treated with cholinesterase inhibitors. Archives of Internal Medicine. 2012; 172: 648-653.
  • Pariente A, Fourrier-Réglat A, Bazin F, Ducruet T, Dartigues JF, Dragomir A, Perrault S, Moore N, Moride Y. Effect of treatment gaps in a cohort of demented elderly treated with cholinesterase inhibitors Neurology 2012 Mar 27;78(13):957-63.
Top

2011

  • Béland SG, Ducruet T, Tournier M, Pariente, A, Galbaud Du Fort G, Crott R, Moride Y. Economical impact of non-persistence with antidepressant therapy in the adult population of Quebec: A comparative Cost-effectiveness approach. Value in Health 2011; 14 : 492-498.
  • Pariente A, Abou Chakra CN, Pinet M, Nkeng L, Moride Y. The value of case series in adverse drug reaction assessment.  Adverse Drug Reaction Bulletin 2011; 270: 1039-1042.
  • Tagalakis V, Kondal D, Ji Y, Boivin JF, Moride Y, Ciampi A, Kahn SR.Men had a higher risk of recurrent venous thromboembolism than women: a large population study. Gend Med. 2012 Feb;9(1):33-43.
  • Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, Limosin F, Beaufils B, Vaiva G, Verdoux H, Moride Y, Fabre A, Thibaut F, Abenhaim L, for the CGS Study Group*.Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the French Cohort for the General study of Schizophrenia (CGS).  Schizophrenia Research.2012 Feb;134(2-3):187-94.
  • Pariente A, Abou Chakra CN, Pinet M, Nkeng L, Moride Y.  The value of case series in adverse drug reaction assessment: consideration from a qualitative systematic review of case series.  Adverse Drug Reaction Bulletin
Top

2010

  • Béland SG, Préville M, Dubois MF, Lorrain D, Voyer P, Bossé C, Grenier S, Moride Y; Scientific Committee of the ESA Study.The association between length of benzodiazepine use and sleep quality in older population. International Journal of Geriatric Psychiatry 2010. Oct. 20 (Epub ahead of print).
  • Béland SG, Preville M, Dubois MF, Lorrain D, Grenier S, Voyer P, Perodeau G, Moride Y. Benzodiazepine use and quality of sleep in the community-dwelling elderly population.  Aging Ment Health. 2010 Sep;14(7):843-50.
  • Abou Chakra L, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y.  Case series in drug safety: A review of published studies.  Drug Safety 2010; 33: 1081-1088
  • Tournier M, Greenfield B, Galbaud du Fort G, Ducruet T, Magno Zito J, Cloutier AM,  Moride Y. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Research 179; 2010: 57-63.
  • Blin P, Blazejewski S, Lignot S, Lassalle R, Bernard MA, Jayles D, Théophile H, Bénichou J, Demeaux JL, Ebbo D, Franck J, Moride Y, Peyramond D, Rouveix B, Sturkenboom M, Gehanno P, Droz C, Moore N. Effectiveness of antibiotics for acute sinusitis in real-life medical practice.  J. Clin. Pharmacol. 2010 70: 418-428.
  • Pariente A, Pinet M, Moride Y, Merlière Y, Moore N, Fourrier-Réglat A. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.  & Drug Saf. 2010; 19: 680-686.
  • Laharie D, Droz-Perroteau C, Benichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A. and Moore, N. on behalf of the CADEUS team. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. British Journal of Clinical Pharmacology 2010; 69: 295-302.
Top

2009 – 2000

  • Rossignol M, Abouelfath A, Lassalle R, Merlière Y, Droz C, Bégaud B, Depont F, Moride Y, Blin P, Moore N, Fourrier-Réglat A. The CADEUS study: Burden of non-steroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers” , Br. J.  Pharmacol. 2009;  67: 188-124.
  • Tournier M, Moride Y, Galbaud du Fort G, Ducruet T, Abenhaim L. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Discord. 2008 Aug 9.
  • Tournier M, Lagnaoui R, Moride Y, Wolfson C, Bégaud B, Moore N. The risk of cognitive impairment in elderly community-dwelling women after benzodiazepine use.  Age & Ageing 2008 (Dec.9, 2008); 1-3.
  • Moride Y., Hegele RA, Langer A., McPherson R, Miler DB, Rinfret S. Clinical and Public Health Assessment of Benefit-risk of Statins in the Primary Prevention of Coronary Events: Resolved and Unresolved Issues.  J.Cardiol..April, 2008.
  • Gogovor A, Savoie M, Moride Y, Krelenbaum M, Montague T Contemporary Disease Management In Québec. Healthcare Quarterly 2008; 11: 30-37.
  • Perreault S, Dragomir A, Blais L, Moride Y, Rossignol M, Ste-Marie LG, Fernandes JC. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.  & Drug Saf. 2008; 17: 248-259.
  • Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes J, Perreault S. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.  J. Clin. Pharmacol. 2008; 66: 117-127.
  • Cougnard A, Verdoux H, Grolleau A, Moride Y, Bégaud B, Tournier M. Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: A decision analysis model.  Med. 2008; Dec 9: 1-9.
  • Tournier M, Moride Y, Lesk M, Ducruet T, Rochon S. The depletion of susceptibles effect in the assessment of burden-of-illness: The example of age-related macular degeneration in the community-dwelling elderly population of Quebec.  J. Clin. Pharmacol. Vol 15 2008;e22-e35.
  • Fourrier-Réglat A, Droz-Perroteau C, Bénichou J, Depont F, Amouretti M, Bégaud B, Moride Y, Blin P, Moore N; CADEUS Team. Impact of prescriber nonresponse on patient representativeness.  Epidemiology 2008; 19: 186-190.
  • Mikaeloff Y, Moride Y, Khoshnood B, Bréart G. Infant and Toddler Disease Score was useful for risk of hospitalization based on data from administrative claims.  Clin. Epidemiol. 2007; 60: 680-685.
  • Tournier M, Moride Y, Ducruet T, Moshyk A, Rochon S. Depression and mortality in the visually-impaired, community-dwelling, elderly population of Quebec. Acta Scand. Ophtalm.2007
  • Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib (Macugen™) compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007;29(9):2096-106
  • Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol. Drug. Saf 2007; 16: 17-27.
  • Martin K, Latry P, Moride Y, Begaud B.[Where can we find French data for pharmacoepidemiology? A few thoughts.] Rev Epidemiol Sante Publique. 2007 Feb 23
  • Omrane R, Eid J, Perreault M, Yazbeck H, Berbiche D, Gursahaney A, Moride Y. Impact of a protocol for prevention of ventilator-associated pneumonia.  Pharmacother. 2007; 41: 1390-1396.
  • Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y on behalf of the CADEUS team. Channeling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and NSAIDs description of users (CADEUS) study.  Pharmacoepidemiology & Drug Safety, 2007; 16: 891-900.
  • Depont F, Fourrier A, Merlière, Droz C., Amouretti, Bégaud B, Bénichou J, Moride Y., Blin P., Moore N on behalf of the Cadeus Study Team. The CADEUS study: methods and logistics. Pharmacoepidemiol. & Drug Safety, 2007; 16: 571-580.
  • Molokhia M, McKeigue P. et al.  EUDRAGENE: European collaboration to establish a case–control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 2006, 7(4), 633-638.
  • Moride Y, Ducruet T, Boivin J, Rochon S, Lavoie F. Utilization of non-steroidal anti-inflammatory drugs in Quebec: Adherence to the Canadian consensus on prescription guidelines.  J.Clin.Pharmacol. 2005; 12: e201-e211.
  • Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S. Prescription channeling of COX-2 inhibitors and traditional non-selective nonsteroidal anti-inflammatory drugs: a population-based case-control study.  Arthritis Research & Rheumatology 2005; 7: R333-342.
  • Martin K, Moride Y, Metge C, Moore N, Bégaud B. Potential impact of oral contraceptive choice on Myocardial Infarction mortality and Deep Vein Thrombosis. J Fam Plann Reprod Health Care 2005.
  • Perreault S, Levinton C, Moride Y, Laurier C, Bellavance F, Crott R. Validation of decision model for pharmacological primary prevention in postmenopausal women.  J. Epidemiol. 2005;20(1):89-101.
  • Perreault S, Dragomir A, Blais L, Rossignol M, Desgagné A, Ste-Marie LG, Fernandes, Moride Y. Trends in and determinants of antiresorptive drug use among elderly women. Drug Saf 2005 :14 :685-695
  • Bégaud B, Martin K, Abouelfath A, Tubert-Bitter B, Moore N, Moride Y. An easy to use method to approximate the Poisson confidence limits.  J. Epidemiol. 2005.
  • Perreault S, Levinton C, Moride Y, Laurier C., Bellavance F, Crott R. « Validation of decision model for pharmacological primary prevention in postmenopausal women ».  Eur J Epidemiol, 2005, 20:89-101.
  • Moore N, Diris H, Martin K, Viale R, Fourrier A, Moride Y, et al. NSAID use profiles derived from reimbursement data in France. Therapie 2004; 59(5):541-6.
  • Moride Y., Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific nonsteroidal anti-inflammatory drugs (NSAIDs) in Quebec. 2003 Nov; 42 Suppl 3:iii17-22.
  • Lagnaoui R, Moore N, Moride Y, Miremont-Salamé G, Bégaud B. Benzodiazepine utilization patterns in Alzheimer’s disease patients. Pharmacoepidemiol Drug Saf, 2003; 12: 511-515.
  • Bégaud B, Fourrier A, Moore N, Moride Y. The delusion of reducing sample size.  J. Clin. Pharmacol 2003.
  • Caron E, Bussières JF, Lebel D, Milot J, Mathews S, Jacob, Moride Y, Lortie L. Ondansetron and droperidol as antiemetics in strabismus.  Can J Ophtaml. 2003; 38: 214‑
  • Kakuma R, Galbaud du Fort G, Perrault A, Arsenault L, Wolfson C, Arsenault L, Platt RW, Monette J, Moride Y. Nondetection of delirium in the emergency room: impact on survival. Am. Ger. Soc. 2003.  Apr; 51(4):443-450.
  • Moride Y, Du Fort GG, Monette J, Ducruet T, Boivin JF, Champoux N et al. Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics. J Am Geriatr Soc 2002; 50(8):1365-1371.
  • Rossignol M, Moride Y, Perreault S, Boivin JF, Ste-Marie LG, Robitaille Y, Poulin de Courval L, Fautrel B. Recommendations for the prevention of osteoporosis and fragility fractures: International comparison and synthesis. Int J Technol Assess Health Care 2002;18(3):597-610
  • Laurier C, Moride Y, Kennedy WA. Health survey data on potentially inappropriate geriatric drug use. Ann Pharmacother 2002; 36(3):404-409.
  • Wolfson C, Perrault A, Moride Y, Esdaile JM, Abenhaim L, Momoli F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer’s disease: are they protective? Neuroepidemiology 2002; 21(2):81-86.
  • Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y. Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002; 24(6):862-886.
  • Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, Moride Y. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002; 55(3):314-318.
  • Egan MY, Wolfson C, Moride Y, Monette J. High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates. BMC Geriatr 2001; 1(1):4.
  • Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M (2001). Review: Donepezil, metrifonate, rivastigmine, and Gingko Biloba are more effective than placebo in Alzheimers’s Disease.  Evidence-Based Mental Health, 4(1)24- with accompanying expert commentary by Dr. J. Pearck, The Fulbrook Centre, Oxford U.K. A modified version with commentary also appears in the American College of Physicians Journal Club.  Vol 134 (1).
  • Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord 2001; 12(3):232-236.
  • Monette J, Galbaud du FG, Fung SH, Massoud F, Moride Y, Arsenault L. Evaluation of the Confusion Assessment Method (CAM) as a screening tool for delirium in the emergency room. Gen Hosp Psychiatry 2001; 23(1):20-25.
  • Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc 2000; 48(7):811-816.
  • Egan M, Wolfson C, Moride Y, Monette J. Do patient factors alter the relationship between physician characteristics and use of long-acting benzodiazepines? J Clin Epidemiol 2000; 53(11):1181-1187.
Top

1999 – 1992

  • Alvarez-Requejo A, Carvajal A., Bégaud B, Moride Y, Vega T, Martin Arias L. Under-reporting of adverse drug reactions.  J. Clin. Pharmacol. 1998; 54: 483-488.
  • Moride Y, Melnychuk D., Monette J., Abenhaim L. Determinants of initiation and sub-optimal use of anti-ulcer medication: a study of the Quebec older population. J. Am. Geriatr. Soc. 1997; 45: 853-856.
  • Moride Y, Haramburu B., Bégaud B., Alvarez-Requejo A., Chaslerie A. Under-reporting of adverse drug reactions in general practice .  J. Clin. Pharmacol. 1997; 43: 177-181.
  • Haramburu F., Bégaud B., Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions.  J. Clin. Pharmacol. 1997; 44: 299-301.
  • Abenhaim L., Moride Y., Brenot F., Rich S. et al., and the IPPHS Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension.  New England Journal of Medicine 1996; 335: 609-616.
  • Tubert-Bitter P., Bégaud B., Moride Y., Chaslerie A., Haramburu F. Comparing the toxicity of 2 drugs in the framework of spontaneous reporting: a confidence interval approach. J. Clin. Epidemiol. 1996; 49: 121-123.
  • Henry D., Lim L, Garcia Rodriguez, Perez Guthann, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.  British Medical Journal 1996; 312: 1563-1566.
  • Moride Y., Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research.  Clin. Epidemiol. 1994; 47: 731-737.
  • Abenhaim L., Moride Y. and the IPPHS Working Group. The International Primary Pulmonary Hypertension Study: Methodology and Design.  Chest 1994; 105 suppl.: 37S-41S.
  • Bégaud B. Moride Y., Tubert-Bitter P., Chaslerie A, Haramburu F. False-positives in spontaneous reporting: should we worry about it? J. Clin. Pharmacol. 1994; 38: 401-404.
  • Tubert-Bitter P., Bégaud B., Moride Y., Abenhaim L. Sample size calculations for single group cohort studies in pharmacosurveillance.  Clin. Epidemiol. 1994; 47: 435-439.
  • Bégaud B, Moride Y., Haramburu F. Quality improvement and statistical calculations made on spontaneous reports.  Drug Information Journal 1994; 28: 1187-1195.
  • Bannwarth B., Labat L., Moride Y., Schaeverbeke T. Methotrexate in rheumatoid arthritis: an update.  Drugs 1994; 47: 25-50.
  • Melnychuk D., Moride Y., Abenhaim L. Monitoring of drug utilization in public health surveillance activities: a conceptual framework.  J. Public Health 1993; 84: 45-49.
  • Moride Y., Hayes J.F. Effects of selection for body weight on pituitary and circulating levels of growth hormone in mice.  Journal of Animal Breeding and Genetics 1993; 110: 450-458.
  • Abenhaim L, Moride Y. Risk and its assessment.  Post-Marketing Surveillance 1992; 16: 127-138.